New project to ATTACK cancer
A new research project, spending around €12m in EU money, will investigate how cancer cells evade the human immune system, possibly leading to new treatments.
A new research project, spending around €12m in EU money, will investigate how cancer cells evade the human immune system, possibly leading to new treatments.
An international consortium of 16 partners, co-ordinated by the UK's University of Manchester and including Oxford Biomedica, will collaborate in the five-year ATTACK (adoptive engineered T-cell targeting to activate cancer killing) project. It seeks to refine T-cell mediated immunotherapy, which engineers T-cells with artificial receptors targeting tumours.